NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Braciak, Todd A ^a   Wildenhain, Sarah ^b   Roskopf, Claudia C ^a   Schubert, Ingo A ^c   Fey, Georg H ^d   Jacob, Uwe ^b   Hopfner, Karl Peter ^b   Oduncu, Fuat S ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d SpectraMab GmbH   (Germany)

Author keywords

Acute myeloid leukemia (AML); Antibody dependent cellular cytotoxicity (ADCC); Cancer immunotherapy; Natural killer (NK) cells; Single chain triplebody (triplebodies)

Indexed keywords

ANTIBODY; CD123 ANTIGEN; CD33 ANTIGEN; CELL RECEPTOR; GAMMA INTERFERON; NATURAL KILLER CELL ACTIVATING RECEPTOR; RITUXIMAB; SPM 2 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CASE REPORT; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; LEUKEMIA REMISSION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MONOZYGOTIC TWINS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SIBLING;

ADULT; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION; TWINS, MONOZYGOTIC; YOUNG ADULT;

EID: 84887506002     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-289     Document Type: Article

References (49)

1. Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 2013, 121:4838-4841. 10.1182/blood-2013-03-490482, 23591788.
2. Press release: FDA (US government). 2010, June 21, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm.
3. Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Schernthaner GH, Wacheck V, Selzer E, Sperr WR, Valent P. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest 2007, 37:73-82. 10.1111/j.1365-2362.2007.01746.x, 17181570.
4. Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets 2010, 11:56-71.
5. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119:6198-6208. 10.1182/blood-2011-11-325050, 3383202, 22286199.
6. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, Zeng W, Harrington KH, Klussman K, Westendorf L, Meyer D, Bernstein ID, Senter PD, Benjamin DR, Drachman JG. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate utilizing a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013, (J. A. McEarchern). Jun 14. [Epub ahead of print].
7. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, Henn A, Rattel B, Friedrich M, Baeuerle PA, Mackensen A, Krause SW. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013, 27(5):1107-1115. 10.1038/leu.2012.341, 23178753.
8. Kugler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, Mackensen A, Fey GH. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 2010, 150:574-586. 10.1111/j.1365-2141.2010.08300.x, 20636437.
9. Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F, Schwemmlein M, Stein C, Mentz K, Mackensen A, Fey GH. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 2010, 33:599-608. 10.1097/CJI.0b013e3181dda225, 20551837.
10. Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Martin K, Ghosh S, Braley H, Tomasetig V, Panousis C, Vairo G, Roberts AW, He SZ, Sprigg N, Thomas D, DeWitte M, Lock RB, Lopez AF, Nash A. CSL362: a monoclonal antibody to human interleukin-3 receptor CD123, optimized for NK cell-mediated cytotoxicity of AML stem cells. ASH 2012, 3598. Abstract.
11. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42. 10.1016/j.stem.2009.04.018, 19570512.
12. Roberts AW, He S, Ritchie D, Hertzberg MS, Kerridge I, Durrant ST, Kennedy G, Lewis ID, Marlton P, McLacian AJ. A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML. J. Clin Oncol 2010, 28(15 Suppl):Abstract e13012.
13. Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008, 31:871-884. 10.1097/CJI.0b013e318186c8b4, 18833000.
14. Schubert I, Kellner C, Stein C, Kugler M, Schwenkert M, Saul D, Mentz K, Singer H, Stockmeyer B, Hillen W, Mackensen A, Fey GH. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 2011, 3:21-30. 10.4161/mabs.3.1.14057, 3038008, 21081841.
15. Schubert I, Kellner C, Stein C, Kugler M, Schwenkert M, Saul D, Stockmeyer B, Berens C, Oduncu FS, Mackensen A, Fey GH. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. MAbs 2012, 4:45-56. 10.4161/mabs.4.1.18498, 3338940, 22327429.
16. Schubert I, Saul D, Nowecki S, Mackensen A, Fey GH, Oduncu F. A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs 2013, 6. [Epub ahead of print].
17. Stein C, Schubert I, Fey GH. Natural killer (NK)- and T-cell engaging antibody-derived therapeutics. Antibodies 2012, 1:88-123.
18. Schubert I, Stein C, Fey GH. Dual-targeting for the elimination of cancer cells with increased selectivity. Antibodies 2012, 1:2-18.
19. Jordan CT. Targeting myeloid leukemia stem cells. Sci Transl Med 2010, 2:21-31.
20. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784. 10.1038/sj.leu.2401903, 11021753.
21. Dick JE. Stem cell concepts renew cancer research. Blood 2008, 112:4793. 10.1182/blood-2008-08-077941, 19064739.
22. Jordan CT. Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology. Nat Clin Pract Oncol 2005, 2:224-225.
23. Wertheim GB, Bagg A. Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes. Expert Rev Mol Diagn 2011, 11:361-366. 10.1586/erm.11.19, 21545254.
24. Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N, Dreyfus F, Manenti S, Demur C, Delabesse E, Lacombe C, Mayeux P, Bouscary D, Recher C, Bardet V. High levels of CD34 + CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 2011, 96:1792-1798. 10.3324/haematol.2011.047894, 3232261, 21933861.
25. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002, 99:3661-3667. 10.1182/blood.V99.10.3661, 11986221.
26. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007, 109:323-330. 10.1182/blood-2005-08-027979, 16940427.
27. Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 2012, 26:2019-2026. 10.1038/leu.2012.87, 22446501.
28. Olive D, Anfossi N, Andre P, Rey J, Orlanducci F, Breso V, Peri V, Prebet T, Charbonnier A, Perrot E, Romagne F, Vey N. Long lasting alteration of natural killer cells post-chemotherapy in elderly patients with acute myeloid leukemia (AML). ASH 2009, Abstract 1653.
29. Sanchez CJ, Le Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D, Costello RT. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother 2011, 60:1-13. 10.1007/s00262-010-0898-x, 20697893.
30. Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother 2010, 59:73-79. 10.1007/s00262-009-0724-5, 3721322, 19526239.
31. Baessler T, Charton JE, Schmiedel BJ, Grunebach F, Krusch M, Wacker A, Rammensee HG, Salih HR. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010, 115:3058-3069. 10.1182/blood-2009-06-227934, 20008791.
32. Baessler T, Krusch M, Schmiedel BJ, Kloss M, Baltz KM, Wacker A, Schmetzer HM, Salih HR. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res 2009, 69:1037-1045.
33. Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A, Darley RL. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011, 25:792-799. 10.1038/leu.2011.1, 3093357, 21274000.
34. Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 1996, 10:478-482.
35. Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 2005, 130:218-228. 10.1111/j.1365-2141.2005.05414.x, 16029450.
36. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, Dilber MS. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008, 111:3155-3162. 10.1182/blood-2007-09-110312, 18192509.
37. Lanier LL. NK cell recognition. Annu Rev Immunol 2005, 23:225-274. 10.1146/annurev.immunol.23.021704.115526, 15771571.
38. Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 2006, 35:93-114. 10.1080/08820130500496878, 16531332.
39. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009, 182:4415-4422. 10.4049/jimmunol.0713732, 19299742.
40. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010, 47:115-123. 10.1053/j.seminhematol.2010.01.011, 2848172, 20350658.
41. Epstein MA, Achong BG, Barr YM, Zajac B, Henle G, Henle W. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 1966, 37:547-559.
42. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2009, 184:16-20.
43. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007, 30:607-613. 10.1097/CJI.0b013e318053ed8e, 17667524.
44. Stein C, Kellner C, Kugler M, Reiff N, Mentz K, Schwenkert M, Stockmeyer B, Mackensen A, Fey GH. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol 2010, 148:879-889. 10.1111/j.1365-2141.2009.08033.x, 20064159.
45. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737. 10.1038/nm0797-730, 9212098.
46. Carey JL, McCoy JP, Keren DF. Flow Cytometry in Clinical Diagnosis 2007, Chicago: ASCP Press, 4.
47. Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Kohl U, Durkop H, Engert A, von Strandmann EP. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther 2013, 21:895-903. 10.1038/mt.2013.14, 3616527, 23459515.
48. Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol 2005, 82:389-396. 10.1532/IJH97.05144, 16533740.
49. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999, 93:4116-4124.